Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.49 |
| ▸ | MEN1 | O00255 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6288128 | 0.87 | KMT2A (0.52) | KMT2AALDH1A1MEN1MAPTLMNA | |
| SCHEMBL6288124 | 0.83 | ALDH1A1 (0.47) | KMT2AALDH1A1MEN1MAPTLMNA | |
| SCHEMBL6286023 | 0.82 | ALDH1A1 (0.57) | KMT2AALDH1A1MEN1MAPTLMNA | |
| SCHEMBL6286100 | 0.82 | KMT2A (0.47) | KMT2AALDH1A1MEN1MAPTLMNA | |
| SCHEMBL6286002 | 0.81 | KMT2A (0.50) | KMT2AALDH1A1MEN1MAPTLMNA | |
| SCHEMBL6711323 | 0.80 | KMT2A (0.48) | KMT2AALDH1A1MEN1MAPTLMNA | |
| SCHEMBL6279218 | 0.80 | RIPK1 (0.55) | KMT2AALDH1A1MEN1MAPTLMNA | |
| SCHEMBL6286254 | 0.79 | GSK3B (0.44) | KMT2AALDH1A1MEN1MAPTLMNA | |
| SCHEMBL6286020 | 0.78 | VCP (0.48) | KMT2AALDH1A1MEN1LMNAKDM4E | |
| SCHEMBL6286947 | 0.77 | KMT2A (0.52) | KMT2AALDH1A1MEN1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014759-A1 | 6,5-Fused bicyclic heterocycles | PICARD JOSEPH ARMAND (US) | 2004-01-22 | — | — | US | claimed |
| EP-1294718-A2 | 6,5-FUSED BICYCLIC HETEROCYCLES | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-26 | — | — | EP | claimed |
| WO-2001096336-A2 | 6,5-FUSED BICYCLIC HETEROCYCLES | WARNER-LAMBERT COMPANY (US) | 2001-12-20 | — | — | WO | claimed |
| US-6943174-B2 | 6,5-Fused bicyclic heterocycles | WARNER-LAMBERT COMPANY (US) | 2005-09-13 | — | — | US | disclosed |
| US-6713471-B1 | SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-20040014759-A1 | 6,5-Fused bicyclic heterocycles | PICARD JOSEPH ARMAND (US) | 2004-01-22 | — | — | US | disclosed |
| EP-1294718-A2 | 6,5-FUSED BICYCLIC HETEROCYCLES | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001096336-A2 | 6,5-FUSED BICYCLIC HETEROCYCLES | WARNER-LAMBERT COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014759-A1 | 6,5-Fused bicyclic heterocycles | ALOX15, ALOX5, ALOX15B | KMT2A 4200/4885ALDH1A1 522/4885MEN1 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.